Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA Meetings, Conferences and Workshops

FDA Meetings, Conferences and Workshops

                        FDA Meetings, Conferences, and Workshops: Past Events
          FDA Annual Reports on Conferences


                        Public Calendar - Meetings With FDA Officials Home
          News & Events
          FDA Meetings, Conferences and Workshops
          Biomarker-driven Drug Development for Allergic Diseases and Asthma; Public Workshop - 02/22/2024FDA Meetings, Conferences and Workshops Public
    Event Title
              Biomarker-driven Drug Development for Allergic Diseases and Asthma; Public Workshop


                  February 22, 2024

  Scheduled

    
  Share
    Post
    Linkedin

    Email
    PrintOn This Page
      Meeting Information
                Event MaterialsDate:
          
  


     
           

February 22, 2024   

 
 
        
                                      Time: 
                                      
8:00 AM
    - 5:00 PM
ET

 

     Attend
    Register for This Event
  The Food and Drug Administration (FDA) is announcing a 1-day public workshop, regarding development and use of biomarkers in the regulation of allergenics to treat respiratory and food allergies.

Purpose of Workshop:

This public workshop is intended to be a forum for the exchange of information and perspectives among regulators and academic investigators on the use of biomarkers to monitor, predict efficacy, and evaluate responses to novel therapeutics for allergic diseases. The input from this public workshop will facilitate decisions by regulatory agencies, industry, and clinical investigators on the use of biomarkers in clinical trials for allergenics, biologics and drugs used to treat respiratory allergic disease and food allergy in children and adults.

Goals of the Workshop:

To inform stakeholders of FDA’s biomarker qualification program and requirements for biomarkers to be accepted for use in clinical trials.
	To inform FDA regulators of the status of diagnostic biomarkers and endotypes in respiratory allergic disease.
	To inform FDA regulators of the status of potential prognostic biomarkers in respiratory allergic disease and food allergy.
	To inform FDA regulators of the status of potential cellular and serologic predictive biomarkers that may arise before the measured clinical response to allergen immunotherapy.
	To inform FDA regulators of the status of monitoring/response biomarkers that may act as a surrogate for current clinical endpoints.Background:

Clinical trials to prove efficacy of immunotherapeutics for allergic diseases are often prolonged and difficult to execute. For example, phase 3 studies for seasonal allergic rhinoconjunctivitis require two pollen seasons and are based on clinical scores, which are highly subjective and may vary from year to year depending on pollen counts. Similarly, the “gold standard” for evaluating efficacy for food allergy is a double-blinded food challenge in which the amount of food that triggers an allergic reaction is determined before and after therapy, a time-intensive and unappealing procedure that may hinder recruitment of study subjects. Furthermore, none of these endpoints inform clinical investigators about possible disease modifying activity of the investigated intervention. For example, clinical scores over two pollen seasons cannot predict whether a therapeutic for allergic rhinoconjunctivitis will modify the immune response to prevent sensitivity to additional environmental allergens or progression to asthma. Similarly, decreases in asthma exacerbations over one year cannot definitively predict whether a novel biologic prevents airway remodeling and fibrosis that characterize irreversible end-stage asthma. Considering the current requirements that are necessary to bring allergy therapeutics to phase 3 clinical trials, biomarkers that indicate their efficacy and whether they can truly modify disease outcome at time of licensure would be a major advance in clinical and regulatory science.

Topics for Discussion:

Discussion of the FDA’s biomarker program, including application of “omics” and the role of translational science towards biomarker development
	Discussion of the state of art of biomarkers that may be applied towards development of therapeutics for allergic rhinoconjuctivitis and asthma
	Discussion of the state of art of biomarkers that may be applied towards development of therapeutics for food allergyDate:

February 22, 2024
8:00 AM – 5:00 PM EST

Location:

This is an in-person/virtual hybrid event. For those who wish to attend in person, the workshop will take place in the Great Room, Building 31, FDA White Oak Campus at 10903 New Hampshire Avenue, Silver Spring, MD.

Shuttle transportation will be provided to and from the Walter Washington Convention Center for out-of-town registrants who will be attending the AAAAI Annual Meeting in Washington DC the following day. Visitor parking is also available on the FDA campus (Visitor Parking and Campus Map | FDA). For virtual attendees, the link for viewing/participation will be provided within your Eventbrite confirmation upon registration.

REGISTRATION:

To register for the public workshop, please visit the following website: https://www.eventbrite.com/e/biomarker-driven-drug-development-for-allergic-diseases-and-asthma-workshop-tickets-719280466237. Registration is free and based on space availability. If you need special accommodations due to a disability, please contact Loni Warren Henderson or Sherri Revell no later than February 8, 2024, at the contact information provided below.

FOR FURTHER INFORMATION CONTACT:

Loni Warren Henderson or Sherri Revell, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 1118, Silver Spring, MD 20993, 240-402-8010, or 240- 402-8180, or CBERPublicEvents@fda.hhs.gov (subject line: Biomarkers for Allergic Diseases Workshop).





Event Materials

  Title
            File Type/SizeAgenda for FDA Public Workshop: Biomarker‐Driven Drug Development for Allergic Diseases and Asthma
              pdf               (144.03 KB)

                                                                                  Content current as of:
      01/19/2024
         
                   
Regulated Product(s)
		 BiologicsMore Meetings,
      Conferences, and
      Workshops
        
        FDA Meetings, Conferences and Workshops

          
                        FDA Meetings, Conferences, and Workshops: Past Events
          FDA Annual Reports on Conferences


                        Public Calendar - Meetings With FDA Officials
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop